文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病

低剂量环磷酰胺、氟达拉滨和抗胸腺细胞球蛋白用于儿童重型再生障碍性贫血的人类白细胞抗原相合同胞造血干细胞移植

Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia.
PubMed 文献 · Br J Haematol · 2023-07-25

该研究回顾了2011至2022年间沙特多家机构32例≤14岁获得性重型再生障碍性贫血或非范可尼贫血遗传性骨髓衰竭综合征患儿,采用低剂量环磷酰胺80 mg/kg、氟达拉滨和抗胸腺细胞球蛋白预处理行人类白细胞抗原相合同胞造血干细胞移植,全部植入成功,3年无事件生存率93%、总生存率95%,移植物抗宿主病概率低。

要点

  • 32例患儿全部植入成功,3年无事件生存率93%、总生存率95%。
  • 仅1例急性GVHD II度和1例轻度慢性GVHD,GVHD概率低。
  • 2例发生继发性植入失败或骨髓增生异常综合征。

核心结论

  • 以低剂量环磷酰胺80 mg/kg联合氟达拉滨为基础的预处理方案行造血干细胞移植,在重型再生障碍性贫血/非范可尼贫血遗传性骨髓衰竭综合征中安全有效。

研究设计与样本

  • 回顾性分析2011至2022年间沙特多家机构≤14岁获得性重型再生障碍性贫血或非范可尼贫血遗传性骨髓衰竭综合征患儿的造血干细胞移植资料。
  • 共32例患儿接受人类白细胞抗原相合同胞造血干细胞移植,其中女性17例、男性15例。
  • 预处理方案为低剂量环磷酰胺80 mg/kg、氟达拉滨和抗胸腺细胞球蛋白。
  • 移植物抗宿主病预防采用吗替麦考酚酯和钙调神经磷酸酶抑制剂。

主要发现

  • 9例患者携带致病性突变(ERCC6L2 2例、ANKRD26 2例、TINF2 2例、LZTFL1 1例、RTEL1 1例、DNAJC21 1例),4例患者端粒缩短。
  • 全部32例患者均植入成功。
  • 移植后3年无事件生存率为93%,总生存率为95%。
  • 2例患者发生继发性植入失败或骨髓增生异常综合征。
  • 移植物抗宿主病概率低:急性GVHD II度1例,轻度慢性GVHD 1例。

临床怎么用

  • 原文结论指出,以低剂量环磷酰胺联合氟达拉滨为基础预处理行造血干细胞移植,在重型再生障碍性贫血/非范可尼贫血遗传性骨髓衰竭综合征中安全有效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

When human leucocyte antigen-matched related donors are available, haematopoietic stem cell transplantation (HSCT) in children with severe aplastic anaemia (SAA) represents the standard of care. Cyclophosphamide (Cy) 200 mg/kg and anti-thymocyte globulin (ATG) are frequently administered, but to-date, no standard conditioning regimen exists. In this study, we investigated the efficacy of a unified HSCT conditioning protocol consisting of low-dose Cy 80 mg/kg, fludarabine and ATG. Data were reviewed from children aged ≤14 years with either acquired SAA or non-Fanconi anaemia inherited bone marrow failure syndrome (IBMFS) between 2011 and 2022 at various Saudi institutions. Graft-versus-host disease (GVHD) prophylaxis included mycophenolate mofetil and calcineurin inhibitors. HSCT was performed in 32 children (17 females and 15 males). Nine patients had deleterious mutations (two ERCC6L2, two ANKRD26, two TINF2, one LZTFL1, one RTEL1 and one DNAJC21). Four patients had short telomeres. All 32 patients engrafted successfully. At 3 years post-transplant, the event-free survival was 93% and overall survival was 95%. Two patients experienced secondary graft failure or myelodysplastic syndrome. A low probability of GVHD was observed (one acute GVHD II and one mild chronic GVHD). These data highlight how HSCT using low-dose Cy as part of a fludarabine-based regimen is safe and effective in SAA/non-Fanconi anaemia IBMFS.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Alsultan A, Abujoub R, Alsudairy R, et al. Human leucocyte antigen-matched related haematopoietic stem cell transplantation using low-dose cyclophosphamide, fludarabine and thymoglobulin in children with severe aplastic anaemia. Br J Haematol. 2023. PMID: 37491781. doi:10.1111/bjh.19004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。